HIGH THROUGHPUT SCREENING TO IDENTIFY HIV INHIBITORS

开发和引入针对艾滋病毒的新疗法和局部杀微生物剂仍然是高度公共卫生优先事项。为了帮助填补这些公共卫生空白，NIAID支持来自学术界、私营部门或其他来源的有前途的治疗性和局部杀微生物剂候选药物的临床前开发。该合同提供产品开发服务，采用标准和高通量筛选(HTS)格式的生化和细胞分析。根据该合同提供的服务将帮助各种研究人员获得获得额外资金所需的关键数据，获得预期的合作伙伴关系(用于进一步开发或支持第一阶段试验)，并满足监管机构对研究新药(IND)申请的要求。以高通量形式(即，大于96孔板)的验证性和专门的分析对介入剂进行测试，目的是识别和表征阻断HIV感染、抑制HIV基因表达和复制、和/或治愈HIV感染的受感染细胞的药物。主要活动包括获取化合物文库，调整标准格式分析以适应高通量，以及确定潜在的抗艾滋病毒治疗药物或局部杀微生物剂。

The development and introduction of new therapeutics and topical microbicides against HIV remains a high public health priority. To assist in filling these public health gaps, the NIAID supports preclinical development of promising therapeutic and topical microbicide candidates that emerge from academia, the private sector, or other sources. This contract provides product development services utilizing biochemical and cell-based assays in both standard and high throughput screening (HTS) formats. The services provided under this contract will assist a wide variety of investigators in obtaining critical data needed to acquire additional funding, gain prospective partnerships (either for further development or to support Phase I trials), and fulfill regulatory agency requirements for investigational new drug (IND) applications. Interventional agents are tested in confirmatory and specialized assays in high-throughput format (i.e., greater than 96-well plates) with the objective of identifying and characterizing agents that block HIV infection, inhibit HIV gene expression and replication, and/or cure infected cells of HIV infection. Primary activities including acquiring compound libraries, adapting standard format assays to high throughput, and identifying potential anti-HIV therapeutics or topical microbicides.